Skip to main content

Table 7 The evaluation of refined models by 4 onlien programs

From: First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients

HCV Models Qmean ERRAT ProSA-web Rampage (Ramachandran plot)
NS5A 1a 1  − 0.89 72.8507  − 4.72 94.3%, 3.5%
2  − 0.45 69.6833  − 4.58 93.8%, 3.5%
3  − 1.12 68.1818  − 4.49 93.8%, 4.0%
4  − 0.9 69.6833  − 4.7 93.8%, 3.5%
5  − 0.59 70.5882  −  4.75 93.8%, 4.4%
Itasser  − 4.64 78.733 NA 85.9%, 8.4%
NS5A 3a 1  − 4.45 85.3333  − 4.48 88.7%, 6.5%
2  − 4.09 85.7143  − 4.55 89.2%, 6.5%
3  − 4.46 87.0536  − 4.58 88.7%, 6.9%
4  − 3.98 80.8889  − 4.43 88.7%, 6.9%
5  − 4.34 86.6667  − 4.53 89.2%, 6.5%
Itasser  − 6.56 86.2222 na 73.2%, 18.2%
NS5B 1a 1  − 1.06 83.737  − 10.85 96.3%, 3.2%
2  − 1.14 88  − 10.85 96.1%, 3.2%
3  − 1.19 89.4464  − 10.79 95.6%, 4.1%
4  − 1.16 85.4167  − 10.71 96.1%, 3.2%
5  − 1.10 86.8284  − 10.82 95.6%, 3.7%
Itasser  − 4.17 93.1389 na 87.3%, 8.7%
NS5B 3a 1  − 1.26 86.7241  − 11.59 96.6%, 2.9%
2  − 1.06 92.6117  − 11.35 96.6%, 3.1%
3  − 1.37 91.7241  − 11.49 96.6%,2.9%
4  − 1.25 93.1271  − 11.38 96.%, 2.7%
5  − 1.11 92.4138  − 11.23 96.8%,2.7%
Itasser  − 4.29 94.3493 na 87.1%, 9.3%
  1. The final selcetd models are bolded